UK Markets closed

Exopharm (EX1): Initiation - All the parts for drug delivery development

·3-min read

Edison Investment Research Limited
31-May-2021 / 07:00 GMT/BST

 

London, UK, 31 May 2021

 

Exopharm (EX1): Initiation - All the parts for drug delivery development

We are initiating research on Exopharm, a company focused on providing solutions for the development of targeted therapeutics using extracellular vesicles (EVs). EVs are small packets of material naturally released by cells in the body that are being investigated for their therapeutic properties and for improving drug delivery, and Exopharm has a suite of technology that may be useful for the development and manufacture of EV therapeutics. Its goal is to out-license this platform to one or more major pharmaceutical partners for the development of EV-based drugs.

 

EVs are small packets of plasma membrane that bud from a range of different cell types. They resemble liposomes in some respects because they are composed of a lipid bilayer, but can contain surface proteins and carry a range of molecules important for intracellular signalling, such as nucleotides. They were initially studied as therapeutics in their own right (ie naïve EVs), but are also of great interest in drug delivery (engineered EVs). EVs are readily taken up by cells in a targeted manner and deliver their cargo directly into the cell, and the goal is that these properties can be utilised for tissue-specific delivery of therapeutics. This being said, all programmes in this space are still at a very early stage and some of the first are only now entering the clinic.


Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Nathaniel Calloway +1 646 653 7036 healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        www.linkedin.com/company/edison-group-/

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting